Physician profile
Charles B Stone
NPI 1881700615
$10,059.75
in general payments reported to CMS, 2019-2025
47 companies · $1,678 in 2025
The $1,678 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,989 · 2020: $341 · 2021: $1,267 · 2022: $1,816 · 2023: $1,470 · 2024: $1,500 · 2025: $1,678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,637 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,636.54 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,307.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $785.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $766.62 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $759.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $682.22 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.04 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Abbvie INC. | $362.44 | 2021-2025 | Linzess, Viberzi |
| Amgen INC. | $348.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $323.32 | 2019-2025 | Veozah, Myrbetriq |
| Gilead Sciences, INC. | $320.41 | 2019-2025 | |
| Medtronic, INC. | $294.09 | 2022-2023 | Azure Xt Dr Mri Surescan |
| Sunovion Pharmaceuticals INC. | $288.89 | 2019-2022 | |
| Abbott Laboratories | $282.34 | 2021-2025 | Freestyle Libre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.60 | 2019-2024 | Xifaxan |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $260.63 | 2024-2025 | Lifevest |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.